Kristin Owens, MD
Obstetrics & Gynecology · Memphis, TNNPI 1487074969
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 108 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by AbbVie at 25.4% of the total. 2025 is the largest year on record at $571, 4.4 times the $130 reported in 2019.
Across 108 payments — averaging $19.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$523
- Shield Therapeutics Inc$222
- Exeltis, USA Inc.$158
- Daiichi Sankyo Inc.$134
- Bayer$129
- Millicent US Inc$84
- plus $807 from 22 others
What the payments were for
- Food & beverage$2,050100%
- Education$70%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 21 | $523 |
| Shield Therapeutics Inc | 14 | $222 |
| Exeltis, USA Inc. | 9 | $158 |
| Daiichi Sankyo Inc. | 6 | $134 |
| Bayer | 7 | $129 |
| Millicent US Inc | 5 | $84 |
| Hologic Sales And Service, LLC | 4 | $81 |
| Biogen | 3 | $80 |
| Mayne Pharma Commercial LLC | 5 | $76 |
| Organon | 4 | $59 |
| Novo Nordisk | 3 | $55 |
| Sumitomo Pharma America, Inc. | 3 | $49 |
| Pfizer | 3 | $43 |
| Astellas Pharma US Inc | 2 | $42 |
| Pacira Pharmaceuticals Incorporated | 2 | $40 |
| Merck | 2 | $38 |
| Amgen | 2 | $32 |
| Seqirus USA Inc | 1 | $30 |
| Myovant Sciences Inc. | 2 | $29 |
| Mylan Pharmaceuticals Inc. | 2 | $28 |
| BD | 1 | $21 |
| Coopersurgical, Inc. | 1 | $20 |
| Pharmacosmos Therapeutics Inc. | 1 | $20 |
| Johnson & Johnson | 1 | $17 |
| Scynexis, Inc. | 1 | $17 |
| Medtronic | 1 | $14 |
| Avion Pharmaceuticals | 1 | $13 |
| Channel Medsystems, Inc. | 1 | $5 |
How this compares
$2,057 in reported general payments places this provider in the 65th percentile of 763 obstetrics & gynecology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Estradiol | 12 | $357 |
| Alendronate Sodium | 12 | $37 |
| Zolpidem Tartrate | 11 | $19 |
Paid to pharmacies, not to this prescriber.
Other obstetrics & gynecology in Memphis
- Benjamin ChappellMemphis$37K
- Pallavi KhannaMemphis$18K
- Donna RandolphMemphis$18K
- Linda MosesMemphis$17K
- Belvia CarterMemphis$10K
- Grover MayJohnson City$916K
- John GreenElizabethton$878K
- Brent LaingElizabethton$480K
- Larry FieldsKnoxville$323K
- Michael SwanNashville$146K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.